These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

200 related items for PubMed ID: 26582807

  • 1. The estimated future disease burden of hepatitis C virus in the Netherlands with different treatment paradigms.
    Willemse SB, Razavi-Shearer D, Zuure FR, Veldhuijzen IK, Croes EA, van der Meer AJ, van Santen DK, de Vree JM, de Knegt RJ, Zaaijer HL, Reesink HW, Prins M, Razavi H.
    Neth J Med; 2015 Nov; 73(9):417-31. PubMed ID: 26582807
    [Abstract] [Full Text] [Related]

  • 2. Enhanced antiviral treatment efficacy and uptake in preventing the rising burden of hepatitis C-related liver disease and costs in Australia.
    Sievert W, Razavi H, Estes C, Thompson AJ, Zekry A, Roberts SK, Dore GJ.
    J Gastroenterol Hepatol; 2014 Aug; 29 Suppl 1():1-9. PubMed ID: 25055928
    [Abstract] [Full Text] [Related]

  • 3. The future disease burden of hepatitis C virus infection in Sweden and the impact of different treatment strategies.
    Duberg AS, Blach S, Falconer K, Kåberg M, Razavi H, Aleman S.
    Scand J Gastroenterol; 2015 Feb; 50(2):233-44. PubMed ID: 25515032
    [Abstract] [Full Text] [Related]

  • 4. Impact of improved treatment on disease burden of chronic hepatitis C in New Zealand.
    Gane E, Stedman C, Brunton C, Radke S, Henderson C, Estes C, Razavi H.
    N Z Med J; 2014 Dec 19; 127(1407):61-74. PubMed ID: 25530333
    [Abstract] [Full Text] [Related]

  • 5. Chronic hepatitis C in the Czech Republic: Forecasting the disease burden.
    Fraňková S, Urbánek P, Husa P, Němeček V, Razavi H, Razavi-Shearer D, Chlíbek R, Šperl J.
    Cent Eur J Public Health; 2019 Jun 19; 27(2):93-98. PubMed ID: 31241282
    [Abstract] [Full Text] [Related]

  • 6. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm.
    Razavi H, Waked I, Sarrazin C, Myers RP, Idilman R, Calinas F, Vogel W, Mendes Correa MC, Hézode C, Lázaro P, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Buti M, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cramp ME, Dore GJ, Doss W, Duberg AS, El-Sayed MH, Ergör G, Esmat G, Falconer K, Félix J, Ferraz ML, Ferreira PR, Frankova S, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Gower E, Gschwantler M, Guimarães Pessôa M, Hindman SJ, Hofer H, Husa P, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Marinho RT, Marotta P, Mauss S, Moreno C, Murphy K, Negro F, Nemecek V, Örmeci N, Øvrehus AL, Parkes J, Pasini K, Peltekian KM, Ramji A, Reis N, Roberts SK, Rosenberg WM, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Semela D, Sherman M, Shiha GE, Sievert W, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Van Vlierberghe H, Vandijck D, Wedemeyer H, Weis N, Wiegand J, Yosry A, Zekry A, Cornberg M, Müllhaupt B, Estes C.
    J Viral Hepat; 2014 May 19; 21 Suppl 1():34-59. PubMed ID: 24713005
    [Abstract] [Full Text] [Related]

  • 7. Liver disease burden and required treatment expenditures for hepatitis C virus (HCV) infection in Thailand: Implications for HCV elimination in the new therapeutic era, a population-based study.
    Wasitthankasem R, Vichaiwattana P, Siripon N, Posuwan N, Auphimai C, Klinfueng S, Thanetkongtong N, Vuthitanachot V, Saiyatha S, Thongmai C, Sochoo S, Pongsuwan N, Poovorawan K, Tangkijvanich P, Poovorawan Y.
    PLoS One; 2018 May 19; 13(4):e0196301. PubMed ID: 29689073
    [Abstract] [Full Text] [Related]

  • 8. Microelimination of chronic hepatitis C in Switzerland: modelling the Swiss Hepatitis Strategy goals in eastern, western and northern regions.
    Rusch U, Robbins S, Razavi H, Vernazza P, Blach S, Bruggmann P, Müllhaupt B, Negro F, Semela D.
    Swiss Med Wkly; 2019 Jan 14; 149():w14694. PubMed ID: 30673118
    [Abstract] [Full Text] [Related]

  • 9. The need for treatment scale-up to impact HCV transmission in people who inject drugs in Montréal, Canada: a modelling study.
    Cousien A, Leclerc P, Morissette C, Bruneau J, Roy É, Tran VC, Yazdanpanah Y, Cox J.
    BMC Infect Dis; 2017 Feb 21; 17(1):162. PubMed ID: 28222681
    [Abstract] [Full Text] [Related]

  • 10. Estimates on HCV disease burden worldwide - filling the gaps.
    Wedemeyer H, Dore GJ, Ward JW.
    J Viral Hepat; 2015 Jan 21; 22 Suppl 1():1-5. PubMed ID: 25560838
    [Abstract] [Full Text] [Related]

  • 11. The present and future disease burden of hepatitis C virus (HCV) infections with today's treatment paradigm - volume 2.
    Hatzakis A, Chulanov V, Gadano AC, Bergin C, Ben-Ari Z, Mossong J, Schréter I, Baatarkhuu O, Acharya S, Aho I, Anand AC, Andersson MI, Arendt V, Arkkila P, Barclay K, Bessone F, Blach S, Blokhina N, Brunton CR, Choudhuri G, Cisneros L, Croes EA, Dahgwahdorj YA, Dalgard O, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Estes C, Flisiak R, Gane E, Gower E, Halota W, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kershenobich D, Kostrzewska K, Kristian P, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Norris S, Nurmukhametova E, Nymadawa P, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prabdial-Sing N, Prins M, Radke S, Rakhmanova A, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Seguin-Devaux C, Shah SR, Shestakova I, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Puri P, Razavi H.
    J Viral Hepat; 2015 Jan 21; 22 Suppl 1():26-45. PubMed ID: 25560840
    [Abstract] [Full Text] [Related]

  • 12. Hepatitis C disease burden and strategies to manage the burden (Guest Editors Mark Thursz, Gregory Dore and John Ward).
    Dore GJ, Ward J, Thursz M.
    J Viral Hepat; 2014 May 21; 21 Suppl 1():1-4. PubMed ID: 24713003
    [Abstract] [Full Text] [Related]

  • 13. Strategies to manage hepatitis C virus (HCV) disease burden.
    Wedemeyer H, Duberg AS, Buti M, Rosenberg WM, Frankova S, Esmat G, Örmeci N, Van Vlierberghe H, Gschwantler M, Akarca U, Aleman S, Balık I, Berg T, Bihl F, Bilodeau M, Blasco AJ, Brandão Mello CE, Bruggmann P, Calinas F, Calleja JL, Cheinquer H, Christensen PB, Clausen M, Coelho HS, Cornberg M, Cramp ME, Dore GJ, Doss W, El-Sayed MH, Ergör G, Estes C, Falconer K, Félix J, Ferraz ML, Ferreira PR, García-Samaniego J, Gerstoft J, Giria JA, Gonçales FL, Guimarães Pessôa M, Hézode C, Hindman SJ, Hofer H, Husa P, Idilman R, Kåberg M, Kaita KD, Kautz A, Kaymakoglu S, Krajden M, Krarup H, Laleman W, Lavanchy D, Lázaro P, Marinho RT, Marotta P, Mauss S, Mendes Correa MC, Moreno C, Müllhaupt B, Myers RP, Nemecek V, Øvrehus AL, Parkes J, Peltekian KM, Ramji A, Razavi H, Reis N, Roberts SK, Roudot-Thoraval F, Ryder SD, Sarmento-Castro R, Sarrazin C, Semela D, Sherman M, Shiha GE, Sperl J, Stärkel P, Stauber RE, Thompson AJ, Urbanek P, Van Damme P, van Thiel I, Vandijck D, Vogel W, Waked I, Weis N, Wiegand J, Yosry A, Zekry A, Negro F, Sievert W, Gower E.
    J Viral Hepat; 2014 May 21; 21 Suppl 1():60-89. PubMed ID: 24713006
    [Abstract] [Full Text] [Related]

  • 14. Forecasting the disease burden of chronic hepatitis C virus in Poland.
    Flisiak R, Halota W, Tomasiewicz K, Kostrzewska K, Razavi HA, Gower EE.
    Eur J Gastroenterol Hepatol; 2015 Jan 21; 27(1):70-6. PubMed ID: 25426979
    [Abstract] [Full Text] [Related]

  • 15. The effect of hepatitis C treatment and human immunodeficiency virus (HIV) co-infection on the disease burden of hepatitis C among injecting drug users in Amsterdam.
    Matser A, Urbanus A, Geskus R, Kretzschmar M, Xiridou M, Buster M, Coutinho R, Prins M.
    Addiction; 2012 Mar 21; 107(3):614-23. PubMed ID: 21919987
    [Abstract] [Full Text] [Related]

  • 16. Current and future health and economic impact of hepatitis C in Belgium.
    Vandijck D, Moreno C, Stärkel P, Van Damme P, Van Vlierberghe H, Hindman SJ, Razavi H, Laleman W.
    Acta Gastroenterol Belg; 2014 Jun 21; 77(2):285-90. PubMed ID: 25090835
    [Abstract] [Full Text] [Related]

  • 17. Epidemiology, disease burden, and treatment strategies of chronic hepatitis C virus infections in Saudi Arabia in the new treatment paradigm shift.
    Aljumah AA, Abaalkhail F, Al-Ashgar H, Assiri A, Babatin M, Al Faleh F, Alghamdi A, Al-Hakeem R, Hashim A, Alqutub A, Razavi H, Sanai FM, Al-Swat K, Schmelzer J, Altraif I.
    Saudi J Gastroenterol; 2016 Jun 21; 22(4):269-81. PubMed ID: 27488321
    [Abstract] [Full Text] [Related]

  • 18. Strategies to manage hepatitis C virus (HCV) infection disease burden - volume 2.
    Gane E, Kershenobich D, Seguin-Devaux C, Kristian P, Aho I, Dalgard O, Shestakova I, Nymadawa P, Blach S, Acharya S, Anand AC, Andersson MI, Arendt V, Arkkila P, Baatarkhuu O, Barclay K, Ben-Ari Z, Bergin C, Bessone F, Blokhina N, Brunton CR, Choudhuri G, Chulanov V, Cisneros L, Croes EA, Dahgwahdorj YA, Daruich JR, Dashdorj NR, Davaadorj D, de Knegt RJ, de Vree M, Gadano AC, Gower E, Halota W, Hatzakis A, Henderson C, Hoffmann P, Hornell J, Houlihan D, Hrusovsky S, Jarčuška P, Kostrzewska K, Leshno M, Lurie Y, Mahomed A, Mamonova N, Mendez-Sanchez N, Mossong J, Norris S, Nurmukhametova E, Oltman M, Oyunbileg J, Oyunsuren Ts, Papatheodoridis G, Pimenov N, Prins M, Puri P, Radke S, Rakhmanova A, Razavi H, Razavi-Shearer K, Reesink HW, Ridruejo E, Safadi R, Sagalova O, Sanchez Avila JF, Sanduijav R, Saraswat V, Schréter I, Shah SR, Shevaldin A, Shibolet O, Silva MO, Sokolov S, Sonderup M, Souliotis K, Spearman CW, Staub T, Stedman C, Strebkova EA, Struck D, Sypsa V, Tomasiewicz K, Undram L, van der Meer AJ, van Santen D, Veldhuijzen I, Villamil FG, Willemse S, Zuckerman E, Zuure FR, Prabdial-Sing N, Flisiak R, Estes C.
    J Viral Hepat; 2015 Jan 21; 22 Suppl 1():46-73. PubMed ID: 25560841
    [Abstract] [Full Text] [Related]

  • 19. Is elimination of HCV possible in a country with low diagnostic rate and moderate HCV prevalence?: The case of Greece.
    Gountas I, Sypsa V, Papatheodoridis G, Souliotis G, Razavi H, Hatzakis A.
    J Gastroenterol Hepatol; 2017 Feb 21; 32(2):466-472. PubMed ID: 27403912
    [Abstract] [Full Text] [Related]

  • 20. Low hepatitis C prevalence in Belgium: implications for treatment reimbursement and scale up.
    Litzroth A, Suin V, Wyndham-Thomas C, Quoilin S, Muyldermans G, Vanwolleghem T, Kabamba-Mukadi B, Verburgh V, Jacques M, Van Gucht S, Hutse V.
    BMC Public Health; 2019 Jan 08; 19(1):39. PubMed ID: 30621662
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.